East Rock Diagnostics
East Rock Diagnostics makes brain health measurable. Our Astroscope™ platform isolates astrocyte-derived exosomes—tiny CNS-origin vesicles in blood—to reveal objective, biologically grounded signatures across neurological conditions.
Alongside a CLIA-first, FDA-ready path for clinical assays, we partner with biopharma on research-use services for clinical trials: patient selection and enrichment, responder/non-responder prediction, endpoint discovery, biomarker integration, and centralized sample analysis.
The result is clearer decisions for sponsors today—and, ultimately, better diagnostic support for clinicians and patients.
Welcome to our website
How Astroscope Works
- Blood sample → astrocyte exosomes
Draw ~0.5 mL plasma - Enrich astrocyte-derived exosomes from blood
- Cargo readout → signatures
Quantify targeted proteins/miRNAs/lipids to derive biologically grounded CNS signatures. - Locked models → research-use report
Return de-identified stratification/response scores for trials or diagnosis.
- What we Do: Exosome Technology → Astroscope™
- Blood draw signatures of complex brain states
- Why it matters: CNS-specific signal, repeatable sampling, fits standard workflows.
- How it works Pre-analytics → Capture → Analytics/QC → Model freeze → Report Novel Dx signatures.
- Research-use only (RUO) during development. CLIA-first, FDA-ready path under evaluation.
- Trial design support: endpoint discovery, inclusion/exclusion refinement.
- Patient selection & enrichment: stratification, responder prediction, cohort balancing.
- Central sample analysis (RUO): standardized pre-analytics, blinded processing, QC dashboards.
- Biomarker integration: assay bridging, longitudinal signal analysis, algorithm lock/freeze.
- Data deliverables: de-identified datasets, analysis reports, audit trails